We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2025 it granted stock options to purchase an ...

H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Vanguard Group Inc. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.3% in the fourth quarter, according to the company in its most recent filing with the ...

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...

Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its latest clinical trial.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...